Netherlands-incorporated generics major Mylan (Nasdaq: MYL) and Indian biotech Biocon (BSE: 532523) are a step closer to gaining approval for a biosimilar version of Herceptin (trastuzumab) in the USA.
Herceptin is sold by Genentech, a unit of Swiss pharma major Roche (ROG: SIX), and is used to treat certain HER2-positive breast and gastric cancers.
"It is a major milestone for the Mylan and Biocon collaboration"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze